<?xml version="1.0" encoding="UTF-8"?>
<p>A clinical trial (ChiCTR2000029600) carried out to evaluate the safety and efficacy of favipiravir for the treatment of SARS-Cov-2 conducted in Shenzhen, on 80 patients, concluded that, compared with lopinavir/ritonavir, favipiravir treatment reduced viral clearance time, and 91% of patients showed improved CT scans with few side effects. The drawback of this study was that it was not randomized double-blinded and placebo-controlled [
 <xref rid="B130-jcm-09-02084" ref-type="bibr">130</xref>]. Another multicentered randomized clinical study (ChiCTR200030254) showed that favipiravir treatment increased the seven-day clinical recovery rate from 55.86% to 71.43%, in co-morbidity free COVID-19 patients. Moreover, favipiravir treatment decreased the time of fever reduction and cough relief within co-morbidity free/co-morbidity associated COVID-19 patients [
 <xref rid="B131-jcm-09-02084" ref-type="bibr">131</xref>].
</p>
